MacroGenics

Rockville,  MD 
United States
http://www.macrogenics.com

• Booth: 10055a

MacroGenics is focused on discovering and developing innovative antibody-based therapeutics for the treatment of cancer. Our core scientific expertise is in the field of protein engineering and our product candidates have been created primarily through our proprietary protein engineering platforms, including our DART® bispecific and Fc Optimization platforms. MARGENZA™ (margetuximab-cmkb) is the first product approved by the FDA from MacroGenics’ pipeline.

Brands: https://events.jspargo.com/ASCO21/CUSTOM/MacroGenics%20-%20Background%20DART_header.png

 Press Releases

• 4. MARGENZA Fact Sheet (Apr 19, 2021)
  https://events.jspargo.com/ASCO21/CUSTOM/US-COM-MGA-2100037%20HCP%20Fact%20Sheet%20DIGITAL%20FINAL%204%2012%2021.pdf

• 5. MARGENZA Patient Support (Apr 19, 2021)
  https://events.jspargo.com/ASCO21/CUSTOM/MARGENZA%20PAP%20Enrollment%20Form_Consumer%20FINAL.pdf

• 3. Prescribing Info/Boxed Warning (Apr 19, 2021)
  https://events.jspargo.com/ASCO21/CUSTOM/MARGENZA%20USPI_16December2020_Approval.pdf

• 1. MacroGenics Pipeline (Apr 20, 2021)
  https://www.macrogenics.com/pipeline/

• 2. www.Margenza.com (Apr 20, 2021)
  www.margenza.com

 Products